Management of premenopausal women with primary breast cancer

In 1992, the report by the Early Breast Cancer Trialists' Collaborative Group on the systemic treatment of early breast cancer by hormonal, cytotoxic and immune therapy suggested that the use of chemoendocrine adjuvant therapy could result in a 30-40 per cent proportional reduction in mortality rate for middle-aged women with primary operable breast cancer(1). The present paper is the first population-based survey of the management of breast cancer in premenopausal women since the 1992 publication.